KOSDAQOthers288330

Parataxis Korea

₩416 0.00%2026-11-18 close
Market Cap
₩44.1B
Turnover
₩0
Volume
0 shares
Shares out.
110M
PER
—
PBR
—
EPS
-₩320
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Persistent Losses and Listing Status in Focus at Parataxis Korea

Parataxis Korea has moved its focus from drug development to a bitcoin treasury platform, but its disclosed results show an operating loss in every year from 2022 to 2025, and the delisting decision and the injunction proceedings now define the outlook.

  1. 1

    Disclosed 2025 revenue was KRW 9 million, up 313.2% from the prior year, while the operating loss for the same year was KRW 15.2 billion, far above revenue.

  2. 2

    Quarterly revenue in 2026 was KRW 319 million in Q1, KRW 1.27 billion in Q2 and KRW 791 million in Q3, with Q2 up 299.0% from the prior quarter and the largest quarter in the disclosed series.

  3. 3

    The Q3 2026 operating loss narrowed to KRW 1.54 billion from KRW 3.44 billion a year earlier, but the attributable net loss in Q4 2025 reached KRW 19.2 billion.

  4. 4

    The Korea Exchange's delisting decision in August 2026 and the company's application for an injunction against it have made the listing status the central issue.

  5. 5

    On October 6, 2026, the two companies signed an agreement to rescind the merger contract, which had been approved in April 2026 as an absorption merger by Parataxis Ethereum.

02

Business structure

Parataxis Korea was founded as Bridgebio in September 2015 and focused on drug development. After a phase 2 failure for its idiopathic pulmonary fibrosis candidate BBT-877 and a setback in technology licensing in 2025, the company changed its name and positioned a bitcoin treasury platform as its main business.

Parataxis Holdings, a US-based affiliate, became the controlling shareholder. The company describes itself as the first institutional-grade bitcoin treasury platform in Korea and cites the acquisition of US mining equipment as vertical integration.

Its pipeline in company materials still lists BBT-207 for non-small cell lung cancer, BBT-877, BBT-301 and BBT-209 for pulmonary fibrosis, and BBT-401 for ulcerative colitis. Disclosed revenue, however, was only KRW 2.18 million in 2024 and KRW 9 million in 2025, so drug revenue is not what the reported figures show.

The company attributed its 2025 consolidated revenue to sales at a subsidiary. In December 2025 it completed a KRW 15 billion third-party share issuance and announced it would acquire 100% of Parataxis Korea Fund IV LLC for KRW 15.098 billion, equal to 20.66% of its equity, for financial investment operations.

Its institutional B2B positioning is the core of its customer description. Parataxis Ethereum, a sister listed company, focuses on data security and has a different business structure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩0-₩3.4B—
2025Q4₩0-₩2.1B—
2026Q1₩300M-₩2.1B−642.7%
2026Q2₩1.3B-₩2.3B−179.0%
2026Q3₩800M-₩1.5B−194.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3B-₩43.5B-₩41.7B−1438.7%−80.4%18.5%
2023₩100M-₩40.3B-₩42.5B−40349.3%−220.0%65.7%
2024₩2,178,072-₩19B-₩19.9B−872715.1%−75.9%21.5%
2025₩9,000,000-₩15.2B-₩32.2B−168375.6%−73.7%61.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 3.02 billion in 2022 to KRW 100 million in 2023 and KRW 2.18 million in 2024, before rising 313.2% to KRW 9 million in 2025.

Because revenue is so small, the operating margin reads as extremely negative at -1,438.7% in 2022, -40,349.3% in 2023, -872,715.1% in 2024 and -168,375.6% in 2025.

The operating loss narrowed from KRW 43.5 billion in 2022 to KRW 40.3 billion in 2023, KRW 19 billion in 2024 and KRW 15.2 billion in 2025, but the company has recorded operating losses in each of the four years from 2022 to 2025.

The attributable net loss was KRW 41.7 billion in 2022, KRW 42.5 billion in 2023, KRW 19.9 billion in 2024 and KRW 32.2 billion in 2025, so the loss widened in 2025.

In its 2025 consolidated results, the company attributed the operating improvement to revenue from a subsidiary and cost cuts across the group, and noted a larger non-cash loss from an impairment of intangible assets.

The attributable net loss of KRW 19.2 billion in Q4 2025 was far larger than the operating loss of KRW 2.08 billion for the same quarter, which suggests that items below operating income weighed heavily.

Quarterly operating losses fell from KRW 3.44 billion in Q3 2025 to KRW 1.54 billion in Q3 2026, although Q2 2026 widened to KRW 2.28 billion from the prior quarter. Quarterly revenue in 2026 was KRW 319 million in Q1, KRW 1.27 billion in Q2 and KRW 791 million in Q3.

The attributable net loss over the last four quarters, from Q4 2025 to Q3 2026, totaled KRW 27.8 billion. The disclosed series has no revenue figures for Q3 and Q4 2025. The debt-to-equity ratio was 61.8% at end-2025, up from 21.5% at end-2024.

05

Industry analysis

A bitcoin treasury strategy means a company holds bitcoin as a reserve asset, so price swings in the holdings flow directly into its valuation and earnings. Parataxis Korea presents a platform that pools institutional capital to hold bitcoin and generate returns from its operation.

Press reports in 2025 described plans by Parataxis Holdings to raise Parataxis Korea Fund II, about KRW 170 billion, and Fund III, KRW 33.8 billion, to add capital for bitcoin purchases. Whether those fund plans turned into actual capital inflows should be checked against changes in equity in the disclosures.

Despite the institutional positioning, disclosed revenue was only KRW 9 million in 2025, so the company's position in its industry is hard to confirm from sales.

Listed companies in the same miscellaneous classification, such as MegaStudyEdu and Hansol Paper, operate in education and paper, so they are not useful direct comparisons. The closer reference is the related company Parataxis Ethereum, a separately listed company focused on data security.

In April 2026 Parataxis Ethereum decided to absorb Parataxis Korea through a merger, but the two companies rescinded that merger in October 2026.

Given the difference in business structure, the sector outlook for Parataxis Korea depends largely on how the bitcoin treasury strategy performs and on its ability to raise capital.

06

Outlook

The most concrete plans in the company's disclosures are two. The first is the acquisition of 100% of Parataxis Korea Fund IV LLC, announced in December 2025 with an expected closing date of January 1, 2026.

The second is the signing of an agreement to rescind the merger contract with Parataxis Ethereum on October 6, 2026.

In that disclosure the company said it will keep reviewing ways to enhance shareholder value depending on changes in circumstances, including the outcome of its injunction application against the delisting decision.

The merger, approved in April 2026, was meant to streamline governance and focus the group's businesses and stabilize finances, but rising uncertainty over the merger timetable after the delisting process led to its withdrawal.

The delisting process began with the Korea Exchange's delisting decision on August 19, 2026, and the company filed for an injunction with the Seoul Southern District Court on August 20, 2026. According to the disclosure, trading in its shares has been suspended from August 21, 2026 until a court decision is confirmed.

On the business side, the drug pipeline still appears in company materials, but the company has not presented a fixed clinical timetable. The bitcoin treasury expansion depends on the fund-raising plans reported in 2025, so whether those funds are formed is the largest variable for expansion.

The next checkpoint is how the 2026 annual report presents full-year revenue, the operating loss and listing-related contingencies.

07

Valuation

PER
—
PBR
—
ROE
-66.4%
EPS
-₩320
BPS
—
Dividend per share
₩0

Because the attributable net loss has continued over the last four quarters, the price-to-earnings ratio cannot be calculated. The company pays no dividend, so dividend yield offers little basis for a valuation discussion.

Of the KRW 43.8 billion total equity at end-2025, KRW 43.7 billion belonged to shareholders of the parent, so book net assets are roughly comparable in size to the market capitalization.

Total equity rose from KRW 27.6 billion at end-2024 to KRW 43.8 billion at end-2025, which appears to reflect capital raises including the December 2025 share issuance.

However, these net assets sit alongside a cumulative operating loss pattern, so comparing market capitalization with book value alone does not explain value. Comparisons with past trading bands or industry averages carry limited meaning while the delisting process is ongoing.

In factual terms, the current market value sits near the net asset base of a loss-making company, and the listing status will determine how any multiple comparison applies.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Revenue Base Widening

Revenue rose 313.2% in 2025 to KRW 9 million from KRW 2.18 million in 2024, and quarterly revenue in 2026 reached KRW 319 million in Q1, KRW 1.27 billion in Q2 and KRW 791 million in Q3. Q2 2026 revenue was up 299.0% from the prior quarter.

The company cited revenue from a subsidiary as a driver of its improved results. Operating losses still far exceed revenue in the same period, so it is too early to link revenue growth to an improvement in profit.

Narrowing Operating Losses

The operating loss narrowed from KRW 19 billion in 2024 to KRW 15.2 billion in 2025, and the Q3 2026 operating loss of KRW 1.54 billion was below the KRW 3.44 billion of Q3 2025. The operating cash outflow also shrank from -KRW 40.2 billion in 2022 to -KRW 14.6 billion in 2025.

Cost reductions are showing up in the disclosed figures. The operating margin is still extremely negative, so the improvement is limited as a measure of business performance.

Capital Raising and Expansion Attempts

In December 2025 the company completed a KRW 15 billion third-party share issuance and announced the acquisition of 100% of Parataxis Korea Fund IV LLC for KRW 15.098 billion. Press reports in 2025 described plans to form Funds II and III to add capital for bitcoin purchases.

Total equity at end-2025 was KRW 43.8 billion, up from the end-2024 level. Whether this capital leads to actual expansion is the next point to confirm.

09

Bear factors

Delisting Process and Trading Suspension

The Korea Exchange decided to delist the company on August 19, 2026, and the company applied to the Seoul Southern District Court for an injunction on August 20. According to the disclosure, trading has been suspended from August 21 until a court decision is confirmed.

A correction filing cites a July 1, 2026 delisting resolution by the exchange's listing committee, so the dates differ across disclosures. The injunction outcome will decide whether the listing continues, making this the largest near-term negative factor.

Continued Losses and Accumulated Deficit

The operating loss has been recorded in each year from 2022 to 2025, and the attributable net loss widened to KRW 32.2 billion in 2025 from KRW 19.9 billion in 2024. The attributable net loss over the last four quarters totaled KRW 27.8 billion.

The attributable net loss in Q2 2026 widened to KRW 5.62 billion from the prior quarter. The debt-to-equity ratio rose to 61.8% at end-2025 from 21.5% at end-2024.

Merger Withdrawal and Revenue Volatility

The April 2026 decision to absorb the company into Parataxis Ethereum was withdrawn through an agreement signed on October 6, 2026, with the uncertainty over the delisting process cited as the reason. Quarterly revenue fell 37.9% from KRW 1.27 billion in Q2 2026 to KRW 791 million in Q3.

The disclosed series lacks revenue for Q3 and Q4 2025, which makes the trend hard to read continuously. Swings in quarterly revenue are a negative factor.

10

Risk factors

Listing Continuity Risk

Depending on the outcome of the delisting decision and the injunction, trading could resume or the company could be delisted. If delisting is confirmed, the circulation and liquidity of the shares would be severely restricted. A prolonged suspension would make it hard for shareholders to trade their shares. The company said it will review shareholder value measures depending on changes such as the injunction outcome.

Asset Price Volatility Risk

A bitcoin treasury strategy is exposed to price swings in the assets it holds. A fall in asset prices could be reflected in valuation losses and enlarge the net loss.

The 2025 attributable net loss of KRW 32.2 billion being larger than the operating loss of KRW 15.2 billion shows that non-operating items have been volatile. The weak link between holdings and operating revenue also needs to be watched.

Capital Funding and Financial Risk

The debt-to-equity ratio rose to 61.8% at end-2025 from 21.5% at end-2024, and the operating cash outflow was -KRW 14.6 billion in 2025. The December 2025 KRW 15 billion share issuance and the KRW 15.098 billion fund stake acquisition show capital being deployed quickly.

If fund formation is delayed or abandoned, additional capital raising could be constrained. Less funding room could slow the pace of the business shift.

11

What to watch next

  1. Date to be confirmed (injunction ruling)

    The injunction ruling against the delisting decision will determine whether trading resumes and the listing continues. Its outcome is the premise for all later assessment.

  2. After November 2026 · date not set

    The timing and content of any shareholder-value measures the company announced after withdrawing the merger. Specific steps such as capital raising or asset disposals should be checked.

  3. End of March 2027

    The filing of the 2026 annual report. Full-year revenue, operating loss, attributable net loss and the debt-to-equity ratio as stated in the disclosure are the next checkpoints.

  4. Fund formation date not set

    Whether Funds II and III reported in 2025 are actually formed. If they are, both the room to expand bitcoin holdings and the funding structure would change.

12

Overall view

Parataxis Korea's disclosed results show a small revenue base and an operating loss that has continued from 2022 through 2025. Revenue was KRW 9 million in 2025, and quarterly revenue in 2026 reached the hundred-million-won range, but the operating loss still exceeds revenue.

The operating loss narrowed to KRW 15.2 billion in 2025 and KRW 1.54 billion in Q3 2026, yet the attributable net loss totaled KRW 27.8 billion over the last four quarters, a heavy burden. Total equity grew to KRW 43.8 billion at end-2025, while the debt-to-equity ratio also rose to 61.8%.

On the business side, the company moved from drug development to a bitcoin treasury platform, and fund formation and the fund stake acquisition are presented as the drivers of expansion.

However, the delisting decision and injunction process in August 2026, the trading suspension and the October merger withdrawal together make the listing status the central issue. The next checkpoints are the injunction ruling and the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. innoforest.co.kr
  2. thebionews.net
  3. thevc.kr
  4. cookiedeal.io
  5. sedaily.com
  6. m.news.nate.com
  7. goinsider.kr
  8. v.daum.net
  9. comp.fnguide.com
  10. valueline.co.kr
  11. news.nate.com
  12. ajunews.com
  13. kr.investing.com
  14. markets.hankyung.com
  15. venturesquare.net
  16. news.nate.com
  17. google.com
  18. digitaltoday.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.